RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A comparison of dry powder inhaler dose delivery characteristics using a power criterion
Dunbar, CA., Morgan, B., Van Oort, M., & Hickey, A. (2000). A comparison of dry powder inhaler dose delivery characteristics using a power criterion. PDA Journal of Pharmaceutical Science and Technology, 54(6), 478-484.
A novel method is described that compares the in vitro drug delivery characteristics of different dry powder inhalers (DPIs) based on the power supplied by the air Row. Power is defined as the rate at which work is done by the air flow and is equal to the product of pressure gradient and air flow rate through the inhaler. Tests were conducted to compare the emitted dose and fine particle fraction of the total dose (FPFTD) of the Diskus, Diskhaler, and a proprietary powder dispersion device (PDD) containing fluticasone propionate/lactose powder blends. Three power levels were selected: 1, 2, and 3W, representing a range of inspiratory efforts. The Diskus and PDD were independent of power, delivering consistent doses and fine particle fractions over the range of powers evaluated. Diskhaler was dependent on power, the emitted dose and FPF,, significantly decreasing at the lower power level (1W) (p < 0.005). Diskus and Diskhaler are trademarks of the Glare Wellcome group of companies
